- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03475875
Contact Lenses With New UV-blocker Manufactured With Different Techniques
May 15, 2019 updated by: Johnson & Johnson Vision Care, Inc.
This study is a randomized, 4-visit, double-masked, 2x3 bilateral crossover, dispensing trial.
The study lenses will be worn as daily wear (DW) for a period of two weeks each with one of the study lenses being worn twice.
Each study lens is expected to be worn at least five (5) days per week for at least six (6) hours per day worn.
There will be no washout period between study lenses.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
92
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Foster City, California, United States, 94404
- VRC-West
-
-
Florida
-
Jacksonville, Florida, United States, 32258
- Bartram Eye Clinic
-
-
South Carolina
-
Pickens, South Carolina, United States, 29671
- Pickens Family Eye Care
-
-
Tennessee
-
Memphis, Tennessee, United States, 38111
- Optometry Group, LLC
-
-
Utah
-
Salt Lake City, Utah, United States, 84106
- William J. Bogus, OD, FAAO
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
Potential subjects must satisfy all of the following criteria to be enrolled in the study:
- The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
- Appear able and willing to adhere to the instructions set forth in this clinical protocol.
- Healthy adult males or females age ≥18 years of age with signed informed consent.
- Eligible presbyopes will be those that wear full distance contact lenses in both eyes, then wear reading glasses over them.
- The subject is a current spherical soft contact lens wearer (defined as a minimum of 6 hours of DW per day, at least 5 days per week, for a minimum of 1 month prior to the study) and willing to wear the study lenses on a similar basis.
- Subjects must be able and willing to wear the study lenses at least 6 hours a day, a minimum of 5 days per week.
- The subject's vertex-corrected spherical equivalent distance refraction must be in the range of -1.00 to -6.00 (inclusive) in each eye.
- The subject's refractive cylinder must be ≤ -1.00 D in each eye.
Have spherocylindrical best corrected visual acuity of 20/25+3 or better in each eye.
Exclusion Criteria:
Potential subjects who meet any of the following criteria will be excluded from participating in the study:
- Currently pregnant or lactating.
- Any active or ongoing systemic disease (e.g., Sjögren's Syndrome), allergies, infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g. rheumatoid arthritis), or other bodily diseases or infections, by self-report, which are known to interfere with contact lens wear and/or participation in the study.
- Use of systemic medications (e.g., chronic steroid use) that are known to interfere with contact lens wear. Habitual medications taken by successful contact lens wearers are generally considered acceptable.
- Habitual toric, extended wear, or multifocal contact lens wear.
- Any current use of ocular medication.
- Any known hypersensitivity or allergic reaction to Optifree PureMoist.
- Any previous, or planned (during the course of the study) ocular surgery (e.g., radial keratotomy, PRK, LASIK, etc.).
- Participation in any contact lens or lens care product clinical trial within 14 days prior to study enrollment.
- Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).
- Any active or ongoing ocular allergies, infections or other ocular abnormalities that are known to interfere with contact lens wear and/or participation in the study. This may include, but not be limited to entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or corneal distortion.
- Any Grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA slit-lamp scale.
- Binocular vision abnormality or strabismus.
- Any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that would contraindicate contact lens wear.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TEST/CONTROL/CONTROL
Subjects that are of 18 years or older and current spherical soft contact lens wearers will wear the Test and Control lenses for two weeks each in random order with one of the study lenses being worn twice for a total of 6 weeks per subject.
|
senofilcon A with new UV blocker investigational process
senofilcon A with new UV blocker standard process
|
Experimental: CONTROL/TEST/TEST
Subjects that are of 18 years or older and current spherical soft contact lens wearers will wear the Test and Control lenses for two weeks each in random order with one of the study lenses being worn twice for a total of 6 weeks per subject.
|
senofilcon A with new UV blocker investigational process
senofilcon A with new UV blocker standard process
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Comfort Score
Time Frame: 2- Week Follow-up Evaluation
|
Overall comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire.
CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65.
Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.
Observations from each study period are treated as independent (for the descriptive summary only).
The average of all observations for each lens was reported.
|
2- Week Follow-up Evaluation
|
Overall Vision Score
Time Frame: 2- Week Follow-up Evaluation
|
Overall vision was assessed using the Contact Lens User Experience™ (CLUE) questionnaire.
CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65.
Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.
Observations from each study period are treated as independent (for the descriptive summary only).
The average of all observations for each lens was reported.
|
2- Week Follow-up Evaluation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 19, 2018
Primary Completion (Actual)
April 18, 2018
Study Completion (Actual)
April 18, 2018
Study Registration Dates
First Submitted
March 9, 2018
First Submitted That Met QC Criteria
March 16, 2018
First Posted (Actual)
March 23, 2018
Study Record Updates
Last Update Posted (Actual)
June 4, 2019
Last Update Submitted That Met QC Criteria
May 15, 2019
Last Verified
May 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR-6140
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Correction of Refraction Error
-
UMC UtrechtUnknownAstigmatism | Myopia | Refraction ErrorNetherlands
-
Johnson & Johnson Vision Care, Inc.TerminatedRefractive Error CorrectionUnited States
-
Eye Hospital Pristina KosovoEnrolling by invitationMyopia | Hyperopia | PseudophakiaKosovo
-
Tianjin Eye HospitalCompleted
-
LG ChemCompleted
-
LG Life SciencesCompletedCorrection of Nasolabial Folds
-
LG Life SciencesCompletedCorrection of Nasolabial FoldsChina
-
LG Life SciencesCompleted
-
Croma-Pharma GmbHCompletedPost Market Study Evaluating Princess Filler Lidocaine for the Correction of Nasolabial Folds (FINO)Correction of Nasolabial FoldsAustria
-
Across Co., Ltd.CompletedCorrection of Nasolabial FoldsKorea, Republic of
Clinical Trials on senofilcon A TEST Lens
-
Johnson & Johnson Vision Care, Inc.Completed
-
Coopervision, Inc.CORERecruiting
-
Coopervision, Inc.CORECompletedMyopiaUnited States, Canada
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.CompletedVision DisordersUnited States
-
Graeme YoungVisioncare Research Ltd.Completed
-
Johnson & Johnson Vision Care, Inc.Completed
-
Coopervision, Inc.CORECompletedPresbyopiaUnited States, Canada